#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endocyte appoints vice president of clinical operations

Share on Twitter Share on LinkedIn
Staff writer | West Lafayette, In., USA | May 8, 2013
EndocyteMay 8, 2013, West Lafayette, In., USA - Endocyte, Inc., a biopharmaceutical company, announced that Scot L. Harper has been appointed as vice president of clinical operations.
Dr. Harper brings more than twenty-five years of clinical operations experience to his position at Endocyte. He joins the company from PAREXEL International, where he was the global portfolio director for oncology, overseeing clinical activities for oncology drugs ranging from Phase 1 to Phase 4 of development.

Prior to this position, he was the vice president of Novartis' North American clinical operations, where he managed clinical operations of all stages of development, including products such as Gleevec, Tasigna and Diovan.

Before this, he was at Eli Lilly and Company, where he held a variety of senior roles, most recently senior director of clinical operations, which included oversight of clinical trials in areas including oncology, neuroscience, diabetes and men's health.

Dr. Harper began his career at SmithKline Beecham, where he worked in new product development. He holds a doctorate in cardiovascular physiology from Indiana University School of Medicine, a master's degree in physiology from Indiana University School of Medicine, a master's degree in business from the University of South Alabama and a bachelor's degree in zoology from DePauw University.